Roche Holding AG (SWX:ROG)
Switzerland
· Delayed Price · Currency is CHF 260.70
+2.30 (0.89%)
Jul 1, 2025, 5:34 PM CET
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B
Revenue Growth
+3.23%
P/S Ratio
3.32
Revenue / Employee
604.32K
Employees
103,249
Market Cap
207.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 47.05B |
| Lonza Group AG | 6.57B |
| Alcon | 8.77B |
| Galderma Group AG | 4.02B |
| Sandoz Group AG | 9.41B |
| Straumann Holding AG | 2.50B |
| Sonova Holding AG | 3.87B |
| Ypsomed Holding AG | 748.87M |
Roche Holding AG News
- 1 day ago - Lomiko Metals Announces Ruisseau Graphite Project Exploration Update, La Roche Zone Extension and Fall Workplan - Business Wire
- 1 day ago - Changes to the Roche Enlarged Corporate Executive Committee - GlobeNewsWire
- 7 days ago - Roche Holding AG (RHHBY) Virtual Hematology Investor Conference Transcript - Seeking Alpha
- 8 days ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga
- 11 days ago - Roche's Genentech reports positive results from lymphoma trial - Seeking Alpha
- 11 days ago - Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma - GlobeNewsWire
- 11 days ago - Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma - Business Wire
- 14 days ago - Roche And Prothena: Why Moving On Makes Sense - Seeking Alpha